Search results
Showing 2056 to 2070 of 2084 results for technology appraisal
Public consultation on updates to health technology evaluations manual
A public consultation marking the first update to NICE's health technology evaluations manual is now open.
Cutting-edge robotic surgery gets green light as 11 systems are recommended
Eleven cutting-edge robotic surgery systems have been approved for use, potentially transforming care for thousands of NHS patients undergoing soft tissue and orthopaedic procedures.
NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.
HST routing criteria: encouraging innovation in the treatment of ultra-rare diseases
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging innovation in the treatment of ultra-rare diseases. He also highlights why effective routing is essential to getting the best care to patients across the NHS.
NICE collaboration on streamlined licensing and patient access process for new medicines
Companies can now submit medicines for the new Innovative Licensing and Access Pathway (ILAP) following close collaboration between the NICE, drug regulators, the NHS and equivalent organisations in Scotland.
How NICE manages the potential conflicts of interests of patient experts
People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.
NICE launches refreshed support service for life sciences industry
NICE has launched its refreshed support service for the life sciences sector, NICE Advice.
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.
NICE collaborates with international partner agencies to streamline the confidential marking process
NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and Economic Review changes the way information about health technologies is handled to streamline processes and increase transparency.
People in England could benefit from new endometrial cancer treatment
Innovative new drug for treating endometrial cancer in adults recommended by NICE as an option for use within the Cancer Drugs Fund.
NICE recommends 'game changing' histology independent cancer drug
Larotrectinib (also called Vitrakvi and made by Bayer), is a new treatment for a range of cancers, has been recommended for use in the Cancer Drugs Fund (CDF).
NICE recommends innovative treatment for severe blood disorder for NHS use
Caplacizumab, with plasma exchange and immunosuppression, will be used to treat acute acquired thrombotic thrombocytopenic purpura.
More than 1,000 people each year will benefit from NICE's recommendation.
Thousands of people living with obesity are set to benefit from a new drug which has helped those using it to reduce their weight by more than 10 per cent.
NICE announces start of review of nusinersen Managed Access Agreement
NICE has today (29 October 2020) announced that it has begun the process to review data collected as part of the Managed Access Agreement (MAA) for nusinersen.